|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||Dr. Klaus Dugi, CEO|
Vandria develops novel small molecules induce mitophagy to treat age-related and chronic diseases.
The company is in the the IND-enabling stage targeting:
CNS: Mild Cognitive Impairment, ALS
Muscle: Sporadic Inclusion Body Myositis
Other: Immuno-oncology, IPF, NASH
Vandria is seeking additional investors to complete its Series A financing round of EUR 14 million led by ND Capital. We also seek partners for our new ferroptosis program.